Market Research Logo

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2018

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2018, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Neuromyelitis Optica (Devic’s Syndrome) - Overview
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
2-BBB Medicines BV
Abide Therapeutics Inc
Acer Therapeutics Inc
Alexion Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Biogen Inc
Bionure Farma SL
Boston Pharmaceuticals Inc
Chugai Pharmaceutical Co Ltd
HanAll Biopharma Co Ltd
LFB SA
MedImmune LLC
Vicore Pharma AB
Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles
2B-3201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANV-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-6039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNMAU-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPX-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCT-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
satralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products
Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
Featured News & Press Releases
Oct 10, 2017: Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)
Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
May 10, 2016: Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, a Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand
Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
May 08, 2015: Initiation Of Phase I Clinical Program
Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund
Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by 2-BBB Medicines BV, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Abide Therapeutics Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Acer Therapeutics Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apellis Pharmaceuticals Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma SL, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB SA, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune LLC, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Vicore Pharma AB, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H1 2018
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report